| Studies |
Number of patients assigned to semaglutide |
Semaglutide intervention |
Number of patients assigned to comparator |
Comparator intervention |
Number of patients assigned to placebo |
Mean follow-up (months) |
| Jensen et al. (2023) [5] |
21 |
1.0 mg semaglutide weekly subcutaneous injection (n=20), 14 mg semaglutide daily oral intake (n=1) |
29 |
3.0 mg daily subcutaneous injection liraglutide (n=28), 1.8 daily subcutaneous injection liraglutide (n=1) |
0 |
6 |
| Murvelashvili et al. (2023) [8] |
115 |
1.0 mg semaglutide once weekly |
92 |
3.0 mg daily liraglutide |
0 |
12 |
| O'Neil et al. (2018) [4] |
718 |
Semaglutide: 0.05 mg/day, 0.1 mg/day, 0.2 mg/day, 0.3 mg/day, 0.4 mg/day, 0.3 mg Fast 2 weekly dose escalation (FE)/day, 0.4 mg FE/day |
103 |
3.0 mg daily liraglutide |
136 |
12 |
| Rubino et al. (2022) [10] |
126, 86.2% completed |
2.4 mg semaglutide once weekly |
127, 95.7% completed |
3.0 mg daily liraglutide |
85 |
17 |
| Romero-Gómez et al. (2023) [9] |
73, 71% completed |
1.0 mg semaglutide once weekly |
72, 64% completed |
10.0 mg once weekly dosage of efinopegdutide |
0 |
6 |
